Medtronic plc (MDT) revenue by segment
MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 18/301% above fair value
$100.72−1.60 (-1.56%)
Close on Nov 18, 2026Market cap $128.84BP/E 24.7Yield 2.82%
Doanh thu theo bộ phận của Medtronic plc
Periods
Theo bộ phận kinh doanh
| Doanh thu | FY2026CY2025 | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable segment net sales | $33.08B | $30.73B | $29.65B | $30.73B | $30.96B | – | – | – | – | – | 91.0% | +7.6% |
| Cardiovascular | $13.98B | $12.48B | $11.83B | $11.52B | $11.37B | $10.77B | $10.47B | $11.51B | – | – | 38.4% | +12.0% |
| Neuroscience | $10.29B | $9.85B | $9.41B | $8.96B | $8.78B | $8.20B | $7.73B | $8.18B | – | – | 28.3% | +4.5% |
| Medical Surgical | $8.82B | $8.41B | $8.42B | $7.99B | $8.47B | $8.74B | $8.35B | $8.48B | – | – | 24.2% | +4.9% |
| Other Operating Segments, Including Diabetes | $3.25B | $2.89B | $2.71B | – | – | – | – | – | – | – | 8.9% | +12.3% |
| Diabetes | $3.11B | $2.76B | $2.49B | $2.26B | $2.34B | $2.41B | $2.37B | $2.39B | $2.14B | $1.93B | 8.6% | +13.0% |
| Other operating segment, misc | $135.00M | $137.00M | $221.00M | – | – | – | – | – | – | – | 0.4% | -1.5% |
| Other Operating Segments | – | $137.00M | $221.00M | $495.00M | $727.00M | – | – | – | – | – | – | – |
| Other Segment | – | $137.00M | $221.00M | $495.00M | – | – | – | – | – | – | – | – |
| Restorative Therapies Group | – | – | – | – | – | – | $7.73B | $8.18B | $7.74B | $7.37B | – | – |
| Cardiac & Vascular Group | – | – | – | – | – | – | $10.47B | $11.51B | $11.35B | $10.50B | – | – |
| Minimally Invasive Therapies Group | – | – | – | – | – | – | $8.35B | $8.48B | $8.72B | $9.92B | – | – |
| Lợi nhuận hoạt động | FY2026CY2025 | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $3.67B | $3.34B | $3.08B | $4.52B | $4.60B | $3.85B | $3.72B | $4.53B | – | – | +9.8% |
| Neuroscience | $3.06B | $3.03B | $2.82B | $3.71B | $3.86B | $3.16B | $2.92B | $3.32B | – | – | +1.0% |
| Medical Surgical | $2.13B | $2.07B | $2.19B | $3.05B | $3.70B | $3.02B | $3.04B | $3.26B | – | – | +2.8% |
| Other Operating Segments, Including Diabetes | $106.00M | $214.00M | $96.00M | – | – | – | – | – | – | – | -50.5% |
| Diabetes | – | $491.00M | $394.00M | $383.00M | $588.00M | $598.00M | $546.00M | $739.00M | $634.00M | – | – |
| Other Operating Segments | – | – | $10.00M | -$89.00M | -$31.00M | – | – | – | – | – | – |
| Other Segment | – | $49.00M | $10.00M | -$89.00M | – | – | – | – | – | – | – |
| Restorative Therapies Group | – | – | – | – | – | – | $2.92B | $3.32B | $3.06B | – | – |
| Cardiac & Vascular Group | – | – | – | – | – | – | $3.72B | $4.53B | $4.46B | – | – |
| Minimally Invasive Therapies Group | – | – | – | – | – | – | $3.04B | $3.26B | $3.35B | – | – |
Theo sản phẩm hoặc dịch vụ
Theo khu vực
| Doanh thu | FY2026CY2025 | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | FY2018CY2017 | FY2017CY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total other countries, excluding Ireland | $36.22B | $33.42B | $32.25B | $31.13B | $31.59B | $30.02B | $28.83B | $30.47B | $29.87B | $29.64B | 99.6% | +8.4% |
| International | $18.26B | $16.37B | $15.80B | $14.85B | – | – | – | – | – | – | 50.2% | +11.6% |
| Rest of world | $18.12B | $16.25B | $15.69B | $14.76B | $15.45B | $14.49B | $13.91B | $14.27B | $13.99B | $12.98B | 49.8% | +11.5% |
| United States | $18.10B | $17.17B | $16.56B | $16.37B | $16.14B | $15.53B | $14.92B | $16.19B | $15.88B | $16.66B | 49.8% | +5.4% |
| Ireland | $143.00M | $116.00M | $113.00M | $98.00M | $101.00M | $100.00M | $85.00M | $91.00M | $85.00M | $69.00M | 0.4% | +23.3% |
| Non-U.S. Developed Markets | – | – | $9.98B | $9.41B | $10.13B | $9.82B | $9.29B | $9.63B | $9.63B | $9.09B | – | – |
| Emerging Markets | – | – | $5.82B | $5.45B | $5.43B | $4.78B | $4.71B | $4.73B | $4.45B | $3.96B | – | – |
| Americas | – | – | – | – | – | – | – | – | – | $17.94B | – | – |
| Asia-Pacific | – | – | – | – | – | – | – | – | – | $3.44B | – | – |
| EMEA | – | – | – | – | – | – | – | – | – | $6.74B | – | – |
| China | – | – | – | – | – | – | – | – | – | $1.59B | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Medtronic (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Medtronic, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
Chỉ số vận hành
| Remaining performance obligations (RPO) | FY2026CY2025 | FY2025CY2024 | FY2024CY2023 | FY2023CY2022 | FY2022CY2021 | FY2021CY2020 | FY2020CY2019 | FY2019CY2018 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Remaining performance obligations (RPO) | $400.00M | $300.00M | $500.00M | $600.00M | $925.00M | $1.30B | $1.10B | $900.00M | +33.3% |
Các số lượng và quy mô Medtronic gắn thẻ trong thuyết minh hồ sơ 10-K, 10-Q (XBRL), tính đến cuối mỗi kỳ. Phần phân tách giữ theo cách công ty tự đặt tên; mỗi chỉ số hiện tối đa 15 dòng.
See a number that looks wrong?